FDA Panel Meets Tuesday About Avandia

An FDA panel will meet today to consider whether the diabetes drug Avandia should be pulled off the market.

Avandia used to be one of Glaxosmithkline's best-selling drugs, but dozens of studies have linked it to an increased risk of heart attack.

Ahead of the meeting, government scientists said the company's own study has serious flaws, and actually makes the case against Avandia.

The panel will makes it recommendation to the FDA after it wraps up a two day review of the drug's performance.